| 岳福伟 魏子秀 徐勤成 田飞飞 孙晓斐.不同剂量瑞舒伐他汀对老年冠心病患者疗效及安全性观察[J].,2015,15(10):1888-1890 |
| 不同剂量瑞舒伐他汀对老年冠心病患者疗效及安全性观察 |
| Efficacy and Safety of Different Doses of Rosuvastatin in Treatment ofElderly Coronary Heart Disease Patients |
| |
| DOI： |
| 中文关键词: 冠心病 瑞舒伐他汀 低密度脂蛋白胆固醇 总胆固醇 颈动脉内－中膜厚度 |
| 英文关键词: Coronary heart disease Rasuvastatin Low-density lipoprotein cholesterol Total cholesterol Intima-media thickness |
| 基金项目: |
|
| 摘要点击次数: 1015 |
| 全文下载次数: 1013 |
| 中文摘要: |
| 目的：探讨不同剂量的瑞舒伐他汀对老年冠心病患者的疗效及安全性的影响。方法：抽取2012 年6 月至2013 年6月于我
院住院行冠脉造影检查示冠状动脉临界病变，诊断为冠状动脉粥样硬化性心脏病的患者210 例（≥ 75 岁），随机分为甲组，乙组，
对甲组给予10 mg/d 的瑞舒伐他汀药物口服治疗，乙组给予20 mg/d 的瑞舒伐他汀药物口服治疗，其它协同药物服用方法均采
集。收集患者开始服用瑞舒伐他汀药物前及服用后1 月、6 月、12 月的血生化指标及颈动脉彩超结果，包括低密度脂蛋白胆固醇
（Low-density Lipoprotein Cholesterol, LDL-C），总胆固醇（Total Cholesterol, TC），甘油三脂（Triglyceride, TG），高密度脂蛋白胆固
醇(High-density Lipoprotein Cholesterol, HDL-C)，超敏C 反应蛋白（High Sensitivity C Reactive Protein, hs-CRP），颈动脉内－中膜
厚度（Intima-media thickness, IMT），谷丙转氨酶(Alanine-Aminotransferase, ALT)，观察这些指标服药前后变化的情况。结果：瑞舒
伐他汀药物治疗1 月、6 月、12 月后两组患者指标相比较，乙组患者较甲组患者TC、TG、LDL-C、hs-CRP、IMT 降低更明显，而
HDL-C 升高水平则明显高于甲组，差别有统计学意义（P＜ 0.05）。两组患者之间血生化指标ALT 及药物治疗期间发生瑞舒伐他
汀相关严重不良反应例数，无明显差别（P＞ 0.05）。两组均无因心脏不良事件（MACE 事件）而终止实验的患者。结论：对于老年冠
心病患者，瑞舒伐他汀药物治疗可以获益，高强度的瑞舒伐他汀药物获益更显著，并且是安全的。 |
| 英文摘要: |
| Objective:To explore the efficacy and safety of different doses of rosuvastatin in treatment of elderly coronary heart
disease patients.Methods:Two hundred and ten hospitalized patients (including 75 years old and higher) diagnosed as Coronary
atherosclerotic cardiopathy（CHD）were evenly divided into group A and group B by randomfromJune 2012 to June 2013. The patients
in group A were treated with oral rosuvastatin at the dose of 10 mg/d, and the patients in group B were treated with oral rosuvastatin at
the dose of 20 mg/d. The other cooperative medication methods were collected. Biochemical indicators were measured before and after
one, six, twelve months of treatment, including Low-density Lipoprotein Cholesterol(LDL-C), Total Cholesterol(TC), High Sensitivity C
Reactive Protein (hs-CRP), Triglyceride (TG), High-density Lipoprotein Cholesterol (HDL-C), Alanine-Aminotransferase (ALT), and
Intima-media thickness (IMT).Results:There were significant decrease in LDL-C, TC, hs-CRP, and TG between the two groups before
and after one, six, and twelve months of treatment(P＜0.05). After treatment, the levels of LDL-C, TC, TG, and hs-CRP of group B were
significantly lower than that of group A (P＜0.05), and HDL-C higher level was significantly higher than in group A. There was no
significant difference between the two groups in the level of ALT and the incidences of adverse reactions (P＞0.05). Both group A and
group B had no adverse cardiac events (MACE) and termination of the experiments.Conclusion:For elderly patients with coronary heart
disease in our country, rosuvastatin medication is beneficial, and higher dose of rosuvastatin is safe and more effective against CHD. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
